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Purpose. Pigment epithelium-derived factor (PEDF) is a multifunctional serpin. The purpose of this study is to identify PEDF
protein forms and investigate their biological activities on tumor cell lines. Methods. Recombinant human PEDF proteins were
puriﬁedbycation-andanion-exchangecolumnchromatography.TheyweresubjectedtoSDS-PAGE,IEF,deglycosylation,heparin
aﬃnity chromatography, and limited proteolysis. Cell viability, real-time electrical impedance of cells, and wound healing assays
were performed using bladder and breast cancer cell lines, rat retinal R28, and human ARPE-19 cells. Results. Two PEDF protein
peaks were identiﬁed after anion-exchange column chromatography: PEDF-1 eluting with lower ionic strength than PEDF-2.
PEDF-1 had higher pI value and lower apparent molecular weight than PEDF-2. Both PEDF forms were glycosylated, bound
to heparin, and had identical patterns by limited proteolysis. However, PEDF-2 emerged as being highly potent in lowering cell
viability in all tumor cell lines tested, and in inhibiting tumor and ARPE-19 cell migration. In contrast, PEDF-1 minimally aﬀected
tumor cell viability and cell migration but protected R28 cells against death caused by serum starvation. Conclusion. Two distinct
biochemical forms of PEDF varying in overall charge have distinct biological eﬀects on tumor cell viability and migration. The
existence of PEDF forms may explain the multifunctional modality of PEDF.
1.Introduction
Pigment epithelium-derived factor (PEDF) is a 50kDa se-
creted glycoprotein and a member of the serpin superfam-
ily with no demonstrable protease inhibitory activity [1].
PEDF is associated with several biological processes due to
its antiangiogenic, anti-inﬂammatory, anti-oxidative, neu-
rotrophic, and neuroprotective properties [2]. Moreover, it
has been implicated in another interesting role, as an antitu-
mor and antimetastatic agent with applications in multiple
malignancies such as retinoblastoma, lung, breast, prostate,
ovarianandpancreaticcarcinomas,uvealmelanoma,glioma,
and osteosarcoma [3–8]. PEDF levels are decreased in tumor
cells relative to normal cells, and PEDF addition inhibits
tumor formation and metastasis, blocks angiogenesis, and
induces apoptosis in tumor and endothelial cells. In contrast,
PEDFpromotesretinalcellsurvivalandneuronaldiﬀerentia-
tion,protectsretinalpigmentepithelialcellsagainstoxidative
stress [2, 3, 9] and plays a role in expansion of neural stem
cells [10]. The mechanisms that mediate the multimodal
functionality to PEDF are not clear.
Previous structure-function studies revealed that two
peptide regions toward the amino end of the PEDF polypep-
tide have distinct biological activities [2, 11, 12]. The peptide
region termed 34-mer (amino acid residues Asp44-Asn77 of
the human PEDF sequence) forms alpha helix A of the 3D
structure of human PEDF [13] and confers antiangiogenic
and antitumorigenic properties to the PEDF polypeptide2 Journal of Biomedicine and Biotechnology
[12]. The 44-mer peptide (Val78-Thr121) derived from the
region that forms alpha helices B, C, and part of D exhibits
neurite-outgrowth activity and protects spinal cord motor
neurons against chronic toxicity [11, 14]. A smaller peptide
derived from amino acid positions 82–121 exhibits eﬀective
neuroprotective properties in retinal ischemia [15].
Interestingly, the native PEDF has several isoforms
diﬀering in isoelectric point (pI) values [16, 17] implying
diﬀerencesinposttranslationalmodiﬁcationsofthepolypep-
tide backbone. Duh et al. reported that the secreted human
recombinant PEDF from human embryonic kidney (HEK)
cells has at least two species varying in their carbohydrate
composition of the N-glycosylation site and eﬃcacy of
suppressing vascular endothelial growth factor-induced pro-
liferation and migration of retinal microvascular endothelial
cells [18]. Maik-Rachline and Seger showed that the human
plasma PEDF is a phosphoprotein and that extracellular
phosphorylation converts the recombinant protein from
a neurotrophic to an antiangiogenic factor [19]. Konson
et al. demonstrated that a triple phosphomimetic-altered
PEDF is more eﬃcient than wild-type PEDF in inhibiting
neovascularization and tumor growth in vivo and suppresses
cultured endothelial cell proliferation and cell migration
much better than the wild-type PEDF [20].
Given the above, the aim of this study was to identify
and characterize PEDF isoforms that could contribute to the
complexity of PEDF action and its multifunctional modality.
2. Methods
2.1. Cell Culture. Human bladder carcinoma T24 cells (Cell
Line collection, Lombardi Comprehensive Cancer Center,
passage 33), human breast cancer 231-BR cells [21] (passage
13), mouse breast cancer 4T1-BR5 cells [21] (passage 11),
human breast tumor MDA-MB-231 cells (Cell Line Collec-
tion, Lombardi Comprehensive Cancer Center, passage 6),
mousebreastcancer4T1cells(CellLineCollection,Lombar-
di Comprehensive Cancer Center, passage 9), and rat retinal
R28 (generous gift of Gail Seigel, passages 47–55), were cul-
tured in DMEM medium. Human retinal pigment epithelial
ARPE-19 cells (American Type Culture Collection, passages
27–32) were cultured in DMEM-12 medium. Media were
supplemented with 10% of fetal bovine serum (FBS) and 1%
penicillin/streptomycin and cultures were incubated at 37◦C
with 5% CO2.
2.2. Protein Puriﬁcation. Recombinant human PEDF was
puriﬁed from the culture media of BHK cells harboring an
expression plasmid containing full-length PEDF cDNA [22].
The culture media was concentrated by ammonium sulfate
precipitation and subjected sequentially to cation- and
anion-exchangecolumnchromatographyasdescribedbefore
with the following modiﬁcations [13]. Cation-exchange col-
umn chromatography was performed using a POROS S resin
connected to a BioCAD 700E perfusion chromatography
system, with buﬀer S (20mM Na phosphate, pH 6.5, 50mM
NaCl)andelutionswerewithalineargradientof50–500mM
NaCl in Buﬀer S. PEDF-containing fractions were pooled,
dialyzed against buﬀer Q (50mM Tris-HCl, pH 8) and sub-
jected to POROS Q column chromatography in buﬀer Q
and elutions were done with a linear gradient of 100–
300mM NaCl in buﬀer Q. The PEDF-containing fractions
were pooled, concentrated, and the buﬀer exchanged to PBS
using ultraﬁltration devices (Centricon-30 or Amicon-30,
Millipore). Storage of the ﬁnal samples was at −80◦C.
2.3. Protein Analyses. Proteins were analyzed by SDS-PAGE
using 10–20% polyacrylamide in SDS-Tricine gels (Invitro-
gen) or NuPAGE 10% polyacrylamide gel in Bis-Tris buﬀer
with NuPAGE MOPS-SDS as running buﬀer (Invitrogen)
under reducing conditions, and isoelectric focusing (IEF).
Protein detection was accomplished with Coomassie Blue
stain. PEDF protein identity was conﬁrmed by Western
Blot.AfterseparationbySDS-PAGEelectrophoresis,proteins
were transferred to a nitrocellulose membrane, blocked for
1h at room temperature, and incubated with polyclonal
antibody to PEDF (Bioproducts MD, Inc.) in blocking
solution at 1:5,000 or 1:10,000 dilution, followed by
secondary antibody anti-rabbit IgG (H + L) in a 1:1000
dilution and the Vectastatin ABC Kit (Vector Laboratories)
with colorimetric detection reagent 4-chloro-1-naphthol
(BioRad Laboratories) as substrate. Alternatively, the sec-
ondary antibody was aﬃnity-puriﬁed peroxidase-labeled
goat anti-rabbit IgG (H + L) in a 1:200,000 dilution, and
chemiluminescence detection with Super Signal West Dura
Extended Duration Substrate (Thermo Scientiﬁc) on X-ray
ﬁlms.
Protein concentrations were determined using the Pro-
tein Assay Kit (BioRad) and Beckman DU 640 Spectropho-
tometer. Protein concentration was calculated from absorb-
ance values using the formula:

Absorbance595nm × 3.5μgB S A

÷

Sample volume

μL

×0.2

= protein concentration

mg/mL

.
(1)
Isoelectric focusing was performed using pH 3–7 or pH
3–10IEFgels(Invitrogen),followingmanufacturer’sinstruc-
tions.
2.4. Enzymatic Deglycosylation. Two micrograms of protein
was treated with N-glycosidase F (New England Biolabs,
Ipswich, MA) following a previously described method [17].
Brieﬂy, the protein sample was denatured by boiling in a
solution containing 0.5% SDS, 40mM DTT. To avoid inacti-
vation of the enzyme by SDS, a total of 1% NP-40 in 50mM
sodium phosphate, pH 7.5 was added to the denatured
sample before adding 1000 Units of N-glycosidase F in 20μL
ﬁnal reaction volume. Enzymatic reactions were incubated
at 37◦C for 1h followed by addition of SDS-PAGE sample
buﬀer and samples were boiled for 10min.
2.5. Limited Proteolysis. PEDF was cleaved with limiting
amounts of chymotrypsin. Reaction mixtures contained
chymotrypsin (Worthington, Lakewood, NJ) and PEDF sub-
strate: at a w/w ratio of 1:10 in 80mM Tris-HCl, pH 7.5 andJournal of Biomedicine and Biotechnology 3
100mM CaCl2. Protein amounts were 1μg and incubation
temperature was 25◦C. Incubation times were as indicated.
The reactions were stopped by freezing in dry ice and the
addition of SDS-PAGE sample buﬀer. Reaction products
were analyzed by SDS-PAGE analysis of products.
2.6. Glycosaminoglycan-Binding Assays. Heparin-binding
assays were performed using heparin aﬃnity column chro-
matography as described previously [23]. Hyaluronan-bind-
ing assays were performed using hyaluronan aﬃnity column
chromatography as described before [24].
2.7. RT-CES Assay. The cells were plated on a microplate bi-
osensor platform and real-time electrical impedance of cells
was followed with RT-CES system from ACEA Biosciences
(San Diego, CA) (http://www.aceabio.com) ,as y s t e md e -
scribed previously [25, 26]. T24, 231-BR, and 4T1-BR5 cells
were seeded at 6,000cells per well (a 96-well format) and
allowed to attach for 18h. Then the cells were serum-starved
for 8h followed by addition of serum-free media containing
PEDF. R28 cells were seeded at a density of 3000 cells/well on
16-well strips of 96-well format with microelectrodes. Back-
ground impedance was measured with media alone before
adding the cells. The cells were allowed to attach for 8h with
media containing 5% FBS. This was followed by changing to
media with or without PEDF at the desired concentration.
Real-time electrical cell impendence was monitored every
hour in each well for several hours. Data from two replicates
was averaged.
2.8. Cell Viability Assays. At the end point of the RT-CES
assay, cell viability was measured by determining the relative
levels of intracellular ATP as a biomarker for live cells
using a CellTiter-Glo kit (Promega, Madison, WI) and
following instructions by manufacturer. After 30min of
incubation at room temperature, the incubation solution in
each well was transferred into wells in a 96-well microtiter
plate. The luminescence intensity was measured using an
automated plate reader (Envision, Perkin Elmer, MA). In
parallel experiments, cells cultured in 24-well plates in
triplicateswereimagedandattheendpoint,cellviabilitywas
measured by determining the relative levels of mitochondrial
dehydrogenase activity as live cell biomarker using the
Cell Counting Kit-8 (Dojindo) following instructions by
manufacturer. Cells in each well were incubated with 50μL
of CCK-8 solution diluted 1:25 and incubated for 4h at
37◦C.Absorbanceofeachwellwasmeasuredat450nmusing
an automated plate reader (Envision). In all the cases, the
absorbance reading for background was subtracted from the
readings of samples. Data from replicates were averaged and
statistical analysis was performed by a t-test. A P value of
<0.05 was taken as signiﬁcant.
2.9. In Vitro Migration Assay. Cell migration was assessed
using wound-healing assays. Conﬂuent cultures of ARPE-19
cells on 24-well culture plates and of MDA-MB-231 cells in
6-well plates were scratched with 10-μL pipette tips to create
ﬁxed-width linear “wounds” in the cell monolayers, followed
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Figure 1: Anion-exchange Column Chromatography of PEDF.
Chromatogram of PEDF with a POROS HQ column attached to
BioCad700, running buﬀe ro f5 0m MT r i s - H C l ,p H8 ,a n daﬂ o w
rate of 3mL/min. Elution was with 25 column volumes of a linear
gradient from 100 to 300mM NaCl. On the chromatogram, blue
indicates the O.D. of the sample read at 280nm, magenta indicates
the conductivity. Resolution of load and peak fractions by IEF is
shown in the inset.
by incubation with medium containing indicated concentra-
tions of PEDF. Cell migration was monitored by capturing
the images of linear wound closure using a 2X brightﬁeld
objective in an Olympus 1 × 70 inverted microscope coupled
with a Sony camera. Images were taken immediately after
wounding and later at deﬁned time intervals until complete
closure in the control cultures.
2.10. Mass Spectrometry. Matrix assisted laser desorption
ionization time of ﬂight (MALDI-TOF) mass spectrometry
was performed to determine the average molecular mass of
the two PEDF protein forms. Puriﬁed samples of PEDF-1
(0.8μg/μL) and PEDF-2 (2.5 or 1μg/μL) in PBS were mixed
1:3 (v/v) with a saturated solution of sinapinic acid in
50% acetonitrile, 0.3% triﬂuoroacetic acid, and 0.5μLo f
each sample was spotted onto a stainless steel MALDI
plate. Mass spectra were manually acquired with 100 laser
shots/spectrum using a MALDI Voyager DE-STR (AB Sciex)
in positive ion, linear mode. The spectra were calibrated
using a mixture of BSA and IgG calibration standards (AB
Sciex). Additionally, some samples were mixed 1:1 (v/v)
with the standard and calibrated internally, postacquisition.
Molecular masses of both forms of PEDF were determined
by averaging the means of 5 spectra collected from each of
three sample spots.
3. Results
3.1. Identiﬁcation of Two Forms of the PEDF Protein. Human
recombinant PEDF was puriﬁed from culture media by a
two-step procedure involving sequential cation- and anion-
exchange column chromatography. The chromatogram from
the cation-exchange column showed one broad peak of
PEDFelutingwith200–250mMNaCl,whichwaspooledand
prepared for anion-exchange column chromatography. The
anion-exchange column chromatogram showed two main
protein peaks (Figure 1). Using conductivity values for the4 Journal of Biomedicine and Biotechnology
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Figure 2: Recombinant altered PEDF proteins secreted to the culturing media were analyzed by anion-exchange column chromatography.
Altered PEDF proteins were K146/K147/R149 (2K,1R→3A) and K189/K191/R194/K197 (3K,1R→4A), and FLAG-PEDF. (a) the backbone
of the 3D structure of PEDF (tube in grey) from PDB 1IMV with highlighted location for amino acids K146/K147/R149 (blue) and
K189/K191/R194/K197 (light blue). FLAG tagged PEDF had two tandem repeats of DYKDDDDK on the carboxy-end (C(A)). (b)
Conductivity of PEDF fractions at peaks by anion-exchange column chromatography was determined and plotted.
fractions(18.3mSand21.96mS)wedeterminedthatprotein
in the ﬁrst and second peaks eluted with about 200mM
NaCl and 253 mM NaCl, respectively. Isoelectric focusing
of the proteins revealed a higher pI value for the protein
in the ﬁrst peak (peak 1) (pI = 7) than in the second one
(peak 2) (pI = 6.1). Proteins in fractions from the two
peaks contained PEDF-immunoreactive bands migrating
as ∼50,000-Mr by SDS-PAGE (see Figure 3). In addition
to the IEF gel, Coomassie blue stained SDS-PAGE gels
demonstrated that the PEDF forms were highly pure, and
the proteins from the ﬁrst peak migrated slightly faster than
those in the second peak (see Figure 3). The protein eluting
with lower ionic strength was termed PEDF-1, and the
version eluting with higher ionic strength was labeled PEDF-
2. As determined by MALDI-TOF mass spectrometry, the
average molecular mass (mean ± standard error) of PEDF-
1 was 46,063 ± 13Da and the molecular mass of PEDF-2
was 47,176 ± 87Da, in agreement with the diﬀerences in
migration by SDS-PAGE.
To ﬁnd out how surface exposed charges aﬀect frac-
tionation of PEDF, alterations at positively charged residues
K146/K147/R149 and K189/K191/R194/K197 of PEDF to
neutral side chain residue alanine were prepared. Altered
proteins were as described before [24]. Fractionation by
anion-exchange column chromatography showed that in
both cases two peaks of PEDF were eluted with conductivity
valuessimilartothoseofwild-typePEDF(Figure 2).Recom-
binantPEDFfusedwithtwotandemrepeatsofFLAGpeptide
at the carboxy-end produced by HEK cells [21] was also
subjected to anion-exchange column chromatography under
identical conditions as above. FLAG peptide (DYKDDDDK)
with several acidic amino acid residues would increase the
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Figure 3: Deglycosylation of PEDF-1 and PEDF-2: deglycosylation
of PEDF proteins was performed with PNGase F under denaturing
conditions. Proteins were resolved by SDS-PAGE. (a) Western
blotting of untreated and treated PEDF proteins (0.15μg per lane)
with anti-PEDF. (b) Coomassie blue staining of untreated and
treated PEDF proteins (1.5μg per lane). Migration position of
PNGaseF is indicated on the right side, and molecular weight
markers are on the left.
overall negative charge of the PEDF protein. We found
that FLAG-PEDF eluted in two peaks with higher ionic
strength than the untagged PEDF (with 316mM NaCl and
367mM NaCl, resp.) (Figure 2). These results indicate that
recombinant human PEDF contains at least two isoforms
varyinginchargeandinapparentmolecularweight,andthat
this characteristic is general.Journal of Biomedicine and Biotechnology 5
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Figure 4:(a)ChymotrypsinLimitedProteolysis:reactionsfortheindicatedtimeswereperformedwithmixturescontainingα-chymotrypsin
and PEDF substrate at a ratio of 1:10 (w/w). Reactions were resolved by SDS-PAGE (0.1μg per lane) followed by western blotting with anti-
PEDF. Cleaved and the uncleaved forms are shown to the right. (b) Binding to Heparin. PEDF-1 and PEDF-2 were subjected to heparin-
aﬃnity column chromatography. Unbound (U) and bound (B) material was analyzed by SDS-PAGE and immunostained with anti-PEDF.
3.2. Deglycosylation of PEDF-1 and PEDF-2. To determine
whether the glycosylation attachments on the PEDF-1
and PEDF-2 polypeptide backbones are involved in their
diﬀerences, the proteins were treated with N-glycosidase F
to release Asn-linked oligosaccharides from glycoproteins.
Figure 3 shows that N-glycosidase F digested both PEDF-1
and PEDF-2 causing them to migrate faster by SDS-PAGE.
It indicates that the enzymatic treatment decreased their
apparent molecular weight by identical values of ∼8000.
Both PEDF forms were glycosylated, and the deglycosylated
PEDF-1 still migrated slightly faster than PEDF-2 by SDS-
PAGE. These observations demonstrate that each PEDF-1
and PEDF-2 molecule had similar carbohydrate content of
about 15% attached to an internal asparagine residue and
that it does not account for the diﬀerences between the two
forms PEDF-1 and PEDF-2.
3.3. Limited Proteolysis and Heparin Binding. The overall
protein conﬁrmation of both PEDF forms was analyzed
by limited proteolysis. Treatment with limiting amounts of
chymotrypsin revealed that both PEDF forms had identical
patterns after digestion. By incubation with chymotrypsin at
a protease:substrate ratio of 1:10 (w/w), both PEDF forms
of about 50kDa were digested in a one-step fashion into
a product of about 46kDa, that is, a decrease of ∼4kDa.
Complete substrate utilization was achieved by 60min
(Figure 4(a)). A band corresponding to the released low-
molecular-weight peptide was not readily identiﬁed by
Coomassie Blue staining of the gel. Given that PEDF has
aﬃnity for heparin, we examined binding to heparin by both
forms. Heparin aﬃnity column chromatography showed
that both forms bound to heparin-conjugated beads with
similar aﬃnity (Figure 4(b)). Hyaluronan binding assays
were performed with PEDF-1 and PEDF-2 (data not shown)
and showed similar results. Altogether, the results indicate
that there are no diﬀerences in the overall protein conforma-
tion and in binding aﬃnity to glycosaminoglycans between
the two PEDF forms.
3.4. Eﬀects of PEDF Versions on Tumor Cell Viability. To
compare the antitumorigenic eﬀects of PEDF-1 and PEDF-2,
T24, 231-BR, and 4T1-BR5 cell cultures were incubated with
serum-free medium containing increasing concentrations of
each PEDF form, and monitored, in parallel, in real time,
for cell impedance using a microelectronic system and under
the microscope. Cells treated without PEDF increased the
electricalimpedancerepresentedascellindexvaluewithtime
up to 72–96h. However, the cell index decreased in those
treated with PEDF-2 in a dose-dependent fashion, while
this was not observed with PEDF-1 (Figure 5), suggesting a
diﬀerential eﬀect on lowering the cell number. Examination
under the microscope revealed a decline in cell number
with increasing PEDF-2 additions and not with PEDF-1
with the three types of cells (Figure 6). The numbers of
cells with 100nM PEDF-2 in each case were signiﬁcantly
decreased in each ﬁeld relative to those without or with
PEDF-1. Quantiﬁcation of relative cell numbers using two
diﬀerent biomarkers for live cells, intracellular ATP content,
and mitochondrial dehydrogenase activity at end point
corroborated the observation that PEDF-2 decreased the
viability of each cell type, while PEDF-1 did not have
a signiﬁcant eﬀect (Figure 7). Altogether, treatment with
PEDF-2 resulted in a dramatic direct negative eﬀectin tumor
cell viability in contrast to PEDF-1.6 Journal of Biomedicine and Biotechnology
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Figure 5: Eﬀects of PEDF proteins on real-time electrical cell impedance of T24, 231-BR, and 4T1-BR5 cells in culture: cells were cultured
in complete media to subconﬂuency, followed by serum starvation for 8h, and then media was replaced with fresh media without serum
containing indicated concentrations of recombinant human PEDF-1 or PEDF-2 proteins. Real-time cell impedance was monitored in cells
treated with indicated concentrations of PEDF. Cell index was normalized relative to the cell numbers at the time of PEDF addition (shown
by arrow). Each point is the average of triplicate assays. Error bars indicate average ± SD.
3.5. Eﬀect of PEDF-1 and PEDF-2 on Cancer and RPE Cell
Motility. It has been reported that PEDF inhibits the migra-
tion of breast tumor MDA-MB-231 cells and retinal pigment
epithelial (RPE) cells [20, 27]. Thus, the eﬀect of the PEDF-
1 and PEDF-2 proteins on cell migration was examined in
MDA-MB-231 cells and ARPE-19 cells. For this wound
healing assay, a ﬁxed-width scratch in a cell monolayer was
created and the advancement of the migrating front was
followed in the presence of either PEDF-1 or PEDF-2.
PEDF-2 aﬀected negatively the migration of the MDA-MB-
231 cells, while PEDF-1 was not signiﬁcant (Figure 8(a)).
WoundhealingassaysperformedwithARPE-19cellsshowed
similar results as with the cancer cells (Figure 8(b)). These
observations indicate that PEDF-2 was more eﬃcient than
PEDF-1 in inhibiting cancer and RPE cell migration.
3.6. PEDF-1 Is Active on Retina R28 Cells against Serum-
Starvation-Induced Death. The above results suggest that
PEDF-2 is more eﬃcient than PEDF-1, implying that PEDF-
1 may have lost its activity. It has been reported that PEDF
also protects retina cells against trophic factor depletion [28,
29]. Thus the activity of PEDF-1 was also examined using
a method in which PEDF protects retina cells against death
induced by serum starvation. Figure 9 shows cell viability of
retina R28 cells treated with increasing amounts of PEDF inJournal of Biomedicine and Biotechnology 7
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Figure 6: Imaging of T24, 231-BR, and 4T1-BR5 cells treated with PEDF-1 and PEDF-2 proteins: bright ﬁeld images were taken at the end
point of cells treated with PEDF proteins at concentrations indicated on the top.
serum-free media for 48 hours. Figure 9(a) shows that real-
timecellindexofR28cellsdecreasedalmostlinearlybetween
the20thhourandthe48thhourafterplating.Howevertreat-
ments with increasing concentrations of PEDF-1 prevented
the cell index decrease, which with the highest dose of PEDF
(100nM) even increased from the 20th to the 35th hour after
plating. Quantiﬁcation of relative cell numbers at end point
using intracellular ATP content as biomarker of live cells
corroboratedtheobservationthatPEDF-1increasedviability
of R28 cells in a dose-dependent fashion (Figure 9(b)).8 Journal of Biomedicine and Biotechnology
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Figure 7: Eﬀects of PEDF proteins on viability of T24, 231-BR, and 4T1-BR5 cells in culture: eﬀect of PEDF on cell viability at the treatment
end point. Plot of relative cell numbers quantiﬁed based on intracellular ATP content (shown on the left) and mitochondrial dehydrogenase
activity(shownontheright)asbiomarkersoflivecells.Cellviabilitywasexpressedaspercentageofluminescencevaluesrelativetountreated
controls, and percentage of absorbance at 490nm relative to untreated controls, respectively. Each point is the average of triplicate assays.
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(a)
0h 18h, none 18h, PEDF-1 18h, PEDF-2
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Figure 8: Eﬀect of PEDF proteins on wound healing assay: MDA-MB-231 (a) and ARPE-19 (b) cell monolayers were scratched with a 10-μL
pipette tip to make a wound. Cells were then incubated with media alone or PEDF proteins (20ng/mL) for 48h in (a) and 18h in (b). Images
were taken at the end points and compared to 0h to measure wound healing.
The eﬀects on the retina survival activity of PEDF-2 were
similar to those of PEDF-1 (Figures 9(c) and 9(d)). Alto-
gether, the results show that both PEDF forms PEDF-1 and
PEDF-2 behaved as active survival factor for retina cells in
culture.
4. Discussion
We have identiﬁed two distinct biochemical forms of re-
combinant PEDF, which we termed PEDF-1 and PEDF-
2. The distinction is based on ionic potential, pI values,
and apparent molecular weight and demonstrates that
PEDF-2 has higher overall negative charge than PEDF-1.
PEDF-2 elution required higher ionic potential from anion-
exchange column chromatography; the protein has a lower
pI and migrated slower in SDS-PAGE than PEDF-1. This
characteristicissharedwithPEDFfromdiﬀerentsourcesand
even when it is altered or fused to tags. Altered and FLAG-
tagged PEDF yielded two peaks similar to the wild-type
PEDF (Figure 2), conﬁrming that the existence as two forms
is a general feature of PEDF. Because the protein derives
from one PEDF cDNA sequence transfected into BHK cells,
the sequence of the polypeptide backbone is identical in
both forms. Upon maturation and secretion, the PEDF
versions may have adopted modiﬁcations posttranslational-
ly that confer charge diﬀerences, and in turn grant diversity
in biological activities to PEDF. Isoforms of PEDF have
been described by diﬀerent laboratories. Recombinant PEDF
isoforms were reported to have diﬀerences in carbohydrate
composition at its glycosylation site [18]. PEDF isoforms
have also been reported in peripheral neuropathies, with
fucose residues on the oligosaccharide chain found only
in the isoforms downregulated in neuropathic patients
without pain [30]. Although both PEDF-1 and PEDF-2 are
glycosylated, they diﬀer in apparent molecular weight even
after deglycosylation, suggesting that this is not the main
diﬀerence between them. More recently, it was reported that
the triple phosphomimetic PEDF, EEE-PEDF, containing
three negatively charged glutamic acids instead of serines,
possesses signiﬁcantly increased antiangiogenic, and anti-
cancer activities than wild-type PEDF [20, 31]. However,
our PEDF forms were not phosphorylated (data not shown).
The signiﬁcance of these ﬁndings is that PEDF isoforms10 Journal of Biomedicine and Biotechnology
Time (hrs)
0
0.4
0.8
1.2
1.6
0 10 20 30 40
PEDF-1 (nM)
100
10
1
0
N
o
r
m
a
l
i
z
e
d
 
c
e
l
l
 
i
n
d
e
x
(a)
0
5000
10000
15000
20000
25000
0 1 10 100
PEDF-1 (nM)
R
e
l
a
t
i
v
e
c
e
l
l
n
u
m
b
e
r
s
(b)
P
E
D
F
-
1
P
E
D
F
-
2
0 nM 10 nM 100 nM
(c)
0
1
2
3
R
e
l
a
t
i
v
e
c
e
l
l
n
u
m
b
e
r
01 0 1 0 0
Protein concentration (nM)
PEDF-1
PEDF-2
(d)
Figure 9: Retina R28 Cell Survival Assays: (a) real-time cell impedance monitoring of PEDF cell survival activity in serum-starved R28
cells in the presence of increasing concentrations of PEDF. The cell index was normalized relative to the cell numbers at the time of PEDF
addition. (b) Plot of relative cell numbers quantiﬁed based on intracellular ATP content performed at end point (see (a)). (c) Bright ﬁeld
images of R28 cells were taken at end point (48h) of cells treated with PEDF proteins at concentrations indicated on the top. (d) Plot of
relative cell numbers quantiﬁed based on intracellular ATP content performed at 48h. Each point is the average of duplicate wells. Error bars
indicate average ± SD.
have been identiﬁed in ocular, tumor, and nontumor tissues
[16, 17, 32], and interestingly their distribution varies
between normal and tumor tissues.
Several reports on posttranslational modiﬁcations of
PEDF oﬀer explanations for the multifunctional modality of
PEDF. Similar to our results, Duh et al. [18] puriﬁed two
forms of PEDF, A and B, using cation-exchange column.
Form A eluted at a lower NaCl concentration, that is, less
positively charged and had a slightly larger molecular weight
thanfromB;andPEDFAwasamoreeﬃcientantiangiogenic
form than PEDF B. This implies a match of PEDF-1 to PEDF
B and PEDF-2 to PEDF A. Petersen et al. [33]r e p o r t e d
that a complete map of all post-translational modiﬁcations
revealed that authentic plasma PEDF carries an N-terminal
pyroglutamate blocking group and an N-linked glycan at
position Asn266. They proposed that the pyroglutamate
residue may regulate the activity of PEDF analogously to the
mannerinwhichitregulatesthyrotropin-releasinghormone.
Maik-Rachline et al. [34] demonstrated that extracellular
phosphorylation converts PEDF from a neurotrophic to an
antiangiogenic factor. Later they proposed that diﬀerential
phosphorylation induces variable eﬀects of PEDF, and
therefore contributes to the complexity of PEDF action [19].
Although the observations with PEDF phosphomimetics
match our results, our PEDF forms were not found to be
phosphorylated and therefore, another chemical diﬀerence is
sought for PEDF-1 and PEDF-2 that is yet to be determined.
These observations are in agreement with the idea that theJournal of Biomedicine and Biotechnology 11
multifunctional modality of PEDF may be explained by
diﬀerences in posttranslational modiﬁcations of the PEDF
polypeptide, which may regulate their biological activities.
Given that synthetic peptides 34-mer and 44-mer derived
from PEDF are biologically active, these regions may require
to be properly exposed in the folded protein to interact
with cell surface receptors and trigger the necessary signals
for activity. Posttranslational modiﬁcations may be tools to
open up or expose the active regions in the folded PEDF
protein. It is envisioned that in PEDF-2 the active region for
antitumorigenic activity is more exposed than in PEDF-1.
Other factors that enhance eﬃcacy in PEDF-2 may include
post-translational modiﬁcation(s) that confers an increase in
negative charge to the protein. Further studies to identify
the chemical diﬀerences between the PEDF forms will be
of great interest for the development of second generation
PEDF molecules.
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